



QUARTERLY COMPLIANCE REPORT ON CORPORATE GOVERNANCE

Name of the Listed Entity : ASTRAZENECA PHARMA INDIA LIMITED
Quarter ending : June 30, 2021

ANNEXURE 1

I. Composition of Board Directors												
Title (Mr./Ms.)	Name of the Director	DIN	Category (Chairperson/Executive/Non-Executive/Independent/Nominee)	Initial date of appointment	Date of Re-appointment	Date of cessation	Tenure*	Date of Birth	No. of Directorship in listed entities including this listed entity (Refer Regulation 17A(1) of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [in reference to provision to regulation 17A(1)]	No. of Memberships in Audit/Stakeholder Committee(s) including this listed entity(Refer Regulation 26(1) of Listing Regulations)	No. of Post of Chairperson in Audit/Stakeholder Committee held in listed entities including this listed entity(Refer Regulation 26(1) of Listing Regulations)
Mr.	NARAYAN KEELVEEDHI SESHADRI	00053563	Non-Executive/Independent	06-Jun-12	30-Sep-19	-	5 years	13-Apr-57	4	4	7	3
Ms.	REVATHY ASHOK	00057539	Non-Executive/Independent	02-Dec-16	-	-	5 years	16-Jan-59	4	4	8	2
Ms.	KIMSUKA NARASIMHAN	02102783	Non-Executive/Independent	02-Feb-17	-	-	5 years	03-May-64	2	2	1	0
Mr.	GAGANDEEP SINGH BEDI	07844333	Executive	01-Jul-17	01-Jul-20	-	3 years	26-Dec-71	1	-	1	0
Ms.	WEIYING SARAH WANG	08369289	Non-Executive	13-Mar-19	-	-	-	17-Dec-75	1	-	2	1
Mr.	ANKUSH NANDRA	08737981	Non-Executive	18-May-20	-	-	-	06-Dec-71	1	-	0	0
Mr.	RAJESH MARWAHA	01458768	Executive	02-Dec-16	02-Dec-19	-	3 years	26-Mar-63	1	-	1	0

Whether Regular chairperson appointed : Yes
 Whether Chairperson is related to managing director or CEO : No

II. Composition of Committees					
<i>Name of Committee</i>	<i>Whether Regular chairperson appointed</i>	<i>Name of Committee members</i>	<i>Category (Chairperson/Executive/ Non-Executive/Independent/Noninee)</i>	<i>Date of Appointment</i>	<i>Date of Cessation</i>
Audit Committee	Yes	1. Ms. REVATHY ASHOK	Chairperson /Independent	02-Dec-2016	-
		2. Mr. NARAYAN K SESHADRI	Independent	02-Dec-2016	-
		3. Ms. WEIYING SARAH WANG	Non-Executive	13-Mar-2019	-
Nomination and Remuneration Committee	Yes	1. Ms. KIMSUKA NARASIMHAN	Chairperson/Independent	02-Feb-2017	-
		2. Mr. NARAYAN K SESHADRI	Independent	06-Feb-2013	-
		3. Ms. WEIYING SARAH WANG	Non-Executive	13-Mar-2019	-
		4. Mr. ANKUSH NANDRA	Non-Executive	18-May-2020	-
Stakeholders' Relationship Committee	Yes	1. Ms. WEIYING SARAH WANG	Chairperson/ Non-Executive	11-Nov-2019	-
		2. Ms. REVATHY ASHOK	Independent	02-Feb-2017	-
		3. Mr. GAGANDEEP SINGH BEDI	Executive	01-Jul-2017	-
		4. Mr. RAJESH MARWAHA	Executive	02-Feb-2017	-
Risk Management Committee	Yes	1. Ms. KIMSUKA NARASIMHAN	Chairperson /Independent	06-Feb-2019	-
		2. Mr. GAGANDEEP SINGH BEDI	Executive	06-Feb-2019	-
		3. Mr. RAJESH MARWAHA	Executive	06-Feb-2019	-
		4. Ms. MINA PATEL	Country HR Director	03-Aug-2020	-
		5. Ms. AMARPREET KAUR AHUJA	Site Lead, India Operations	01-Apr-2019	-

III. Meeting of Board of Directors					
<i>Date(s) of Meeting (If any) in the previous quarter</i>	<i>Date(s) of Meeting (if any) in the relevant quarter</i>	<i>Whether requirement of Quorum met</i>	<i>Number of Directors present</i>	<i>Number of independent directors present</i>	<i>Maximum gap between any two consecutive meetings (in number of days)</i>
25-May-2021	09-Aug-2021	Yes	7	3	75

III. Meetings of Committees					
Date(s) of Meeting of the Committee in the relevant quarter	Whether requirement of Quorum met	Number of Directors present	Number of independent directors present	Date(s) of Meeting (if any) in the previous quarter	Maximum gap between any two consecutive meetings (in number of days)
Audit Committee					
9-Aug-2021	Yes	3	2	20-Apr-2021	40
	Yes	3	2	25-May-2021	
	Yes	3	2	29-Jun-2021	
Corporate Social Responsibility Committee					
3-Aug-2021	Yes	3	1	-	-

V. Related Party Transactions	
Subject	Compliance status (Yes / No / NA) refer note below
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Yes
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit committee	Yes

Details of material transactions with Related Party for the quarter ended September 30, 2021

Name of the Related Party: **AstraZeneca UK Limited**

Type of Transaction	Amount (INR)
Imports	836,577,238
Reimbursement of Expenses	2,286,744
Total	838,863,982

Affirmations

1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015
2. The Composition of the following committees is in terms of SEBI (listing Obligations and Disclosure requirements) Regulations, 2015
 - a) Audit Committee
 - b) Nomination & Remuneration Committee
 - c) Stakeholders Relationship Committee
 - d) Risk Management Committee
3. The Committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements Regulations, 2015
4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015
5. This report and /or the report submitted in the previous quarter has been placed before Board of Directors.

Any comments/observations/advice of Board of Directors may be mentioned here: NIL

For **AstraZeneca Pharma India Limited**

Sd/-

Pratap Rudra

Company Secretary & Legal Counsel

ANNEXURE III

Affirmations		
Broad heading	Regulation Number	Compliance status (Yes/No/NA)
<i>Copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report, business responsibility report displayed on website</i>	46(2)	Yes
<i>Presence of Chairperson of Audit Committee at the Annual General Meeting</i>	18(1)(d)	Yes
<i>Presence of Chairperson of the nomination and remuneration committee at the annual general meeting</i>	19(3)	Yes
<i>Presence of Chairperson of the Stakeholders' Relationship Committee at the annual general meeting</i>	20(3)	Yes
<i>Whether "Corporate Governance Report" disclosed in Annual Report</i>	<i>34(3) read with para C of Schedule V</i>	Yes

Annexure IV

Additional Half yearly Disclosure

Applicability of disclosure	Not Applicable
-----------------------------	----------------

For AstraZeneca Pharma India Limited

Sd/-
Pratap Rudra